Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin Appearance Observed in Pediatric Study after Only ...
Additionally, results from preclinical studies provide proof-of-mechanism for recovery of muscle function with ClC-1 inhibition using NMD670 in CMT mouse models Aarhus, Denmark, 18 December 2024 – NMD ...
Soligenix begins confirmatory phase 3 trial of HyBryte for treatment of cutaneous T-cell lymphoma: Princeton, New Jersey Wednesday, December 18, 2024, 14:00 Hrs [IST] Soligenix, I ...